Hangtaimycin derivatives and preparation methods and applications thereof

The Hangtaimycin derivatives HTMA and HTMB isolated and prepared from Streptomyces spectabilis have solved the shortcomings of existing drugs in the treatment of inflammatory pain and liver injury, and achieved excellent anti-inflammatory, analgesic, anti-tumor and liver injury. Protective effect and demonstrate the ability to prevent and treat drug addiction.

CN115385985BActive Publication Date: 2024-11-05WUHAN UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202210639069.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-06-07
Publication Date
2024-11-05
Estimated Expiration
2042-06-07

AI Technical Summary

Technical Problem

The existing anti-inflammatory and liver injury treatment drugs have limited effectiveness in treating inflammatory pain and drug addiction, and it is difficult to have excellent anti-tumor and liver injury protection effects at the same time.

Method used

The Hangtaimycin derivatives HTMA and HTMB were isolated and prepared from Streptomyces spectabilis, and their biological activity was enhanced by alcoholylation, and fermentation cultures of genetically engineered mutant strain ΔhtmP were prepared efficiently, combining SFMR medium and multi-step liquid phase Chromatographic separation technology prepares compounds with excellent anti-inflammatory, analgesic, anti-tumor and liver injury protection effects.

Benefits of technology

HTMA and HTMB significantly improve the anti-inflammatory, analgesic, anti-tumor and liver injury protection effects, and show the prevention and treatment effects of morphine and cocaine addiction, providing a multifunctional drug development prospect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115385985B_ABST
    Figure CN115385985B_ABST
Patent Text Reader

Abstract

The present invention discloses a hangtaimycin derivative and a preparation method and application thereof. The hangtaimycin derivative is obtained by fermenting Streptomyces spectabilis CCTCCM2017417 or its genetically engineered strain in SFMR medium, and further separating, purifying and alcoholyzing the extract. Screening reveals that the hangtaimycin derivative has excellent anti-inflammatory, analgesic, anti-tumor, liver damage protection and drug addiction prevention and treatment activities, providing a new lead compound for the development of related drugs.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of pharmaceutical biotechnology, and specifically relates to a Hangtaimycin derivative and a preparation method and application thereof. Background Art

[0002] Inflammation is a common pathological process of many diseases. Any factor that causes tissue damage can be the cause of inflammation, including: 1) biological factors such as bacteria, viruses, rickettsia, mycoplasma, fungi, spirochetes and parasites; 2) physical factors such as high temperature, low temperature, radioactive substances, ultraviolet rays and mechanical damage; 3) chemical factors such as exogenous chemicals such as strong acids, strong alkalis, turpentine, mustard gas, etc. and endogenous toxic substances such as decomposition products of necrotic tissue and metabolites accumulated in the body under certain pathological conditions. Metabolites, etc.; 4) Foreign bodies such as various metals, wood chips, dust particles, and surgical sutures; 5) Necrotic tissue such as tissue necrosis caused by ischemia or hypoxia; 6) Allergic reactions include type I allergic reactions such as allergic rhinitis and urticaria, type II allergic reactions such as anti-basement membrane glomerulonephritis, type III allergic reactions such as glomerulonephritis caused by immune complex deposition, type IV allergic reactions such as tuberculosis and typhoid fever, and many autoimmune diseases such as lymphocytic thyroiditis and ulcerative colitis. Inflammatory factors can cause pain and are also involved in liver tissue damage, tumorigenesis, drug addiction, and other processes.

[0003] Hangtaimycin (HTM) was first isolated from Streptomyces spectabilis CPCC200148 in 2016. Our research group also isolated HTM from another strain of Streptomyces spectabilis CCTCCM2017417. In order to further investigate the biological activity and application value of HTM derivatives, we used the resin addition method to obtain a large amount of deoxyhangtaimycin (HTMP) from the fermentation product of its cytochrome P450 gene in-frame knockout mutant strain ΔhtmP. For the first time, we prepared new HTM derivatives hangtaimycin A (HTMA) and hangtaimycin B (HTMB) from Streptomyces spectabilis CCTCC M2017417 or its genetically engineered strains (such as ΔhtmP) by alcoholysis, and screened their anti-inflammatory, liver-protective, anti-tumor, analgesic, and therapeutic activities for morphine and cocaine addiction. The present invention shows that this type of compound has excellent liver protection, anti-inflammatory, analgesic, and morphine and cocaine addiction treatment activities, and has a good prospect for being developed into anti-inflammatory and analgesic, anti-tumor, liver damage protection and drug addiction prevention and treatment drugs. It is found that its anti-inflammatory activity has a structure-activity relationship, that is, the removal of the C42 hydroxyl group in the structure of the derivative and the methanolysis of the cyclic dipeptide can enhance its activity, which provides a direction for its further chemical structure modification. Summary of the invention

[0004] 1. The first object of the present invention is to provide a derivative of HTM

[0005] 2. The second object of the present invention is to provide an efficient preparation method of HTMP, HTMA and HTMB, the derivatives of the compound HTM, comprising the following steps:

[0006] To achieve the above object, the technical solution of the present invention is as follows:

[0007] In a first aspect, the present invention provides an HTM derivative, characterized in that it includes alcoholysis derivatives HTMA and HTMB, and its chemical structure is as follows:

[0008]

[0009] Hangtaimycin A:R i =CH 3 ; R 2 =CH 3 ; R 3 =CH 3 ; R 5 =CH 3 ; R 4=H

[0010] Hangtaimycin B:R i =CH 3 ; R 2 =CH 3 ; R 3 =CH 3 ; R 5 =CH 3 ; R 4 =OH

[0011] In a second aspect, the present invention provides a method for preparing a HTM derivative of the above-mentioned compound, characterized in that: the HTM derivative includes alcoholysis derivatives HTMA, HTMB and HTMP, comprising the following steps:

[0012] S1: Streptomyces spectabilis CCTCC M2017417 or its genetically engineered strain uses SFMR medium, wherein the SFMR medium contains the following components: 2% soybean powder, 2% mannitol, and 5% AB-8 macroporous adsorption resin, to prepare the corresponding fermentation culture;

[0013] S2: separating the solid and liquid of the fermentation product in step S1, extracting them with ethyl acetate respectively, and combining the extracts;

[0014] For the preparation of deoxyhangtaimycin, chloroform / acetonitrile is used as the eluent, and gradient elution is performed in a volume ratio from 100:0 to 50:50, and fractions eluted in a volume ratio of chloroform:acetonitrile from 70:30 to 50:50 are collected; or,

[0015] For the preparation of hangtaimycin A and hangtaimycin B, the combined crude extracts were gradient eluted using a chloroform:methanol mixed solvent with a volume ratio ranging from 100:0 to 90:10, and fractions eluted with a chloroform:methanol volume ratio of 96:4 to 94:6 were collected;

[0016] S3: The fractions containing the target deoxyhangtaimycin, hangtaimycin A or hangtaimycin B were further subjected to ODS reverse phase medium pressure liquid chromatography (S-50 μm, 12 nm, 26×300 mm, flow rate 13 mL / min) with acetonitrile / water as the eluent and gradient elution from 0:100 to 100:0 by volume ratio:

[0017] When preparing deoxyhangtaimycin, the above-mentioned fraction containing the target product is finally subjected to high performance liquid chromatography (ODS-A, 250×10 mm, 5 μm, YMC, flow rate of 3 mL / min), and eluted with a gradient of acetonitrile: water from 45% to 55% by volume, and deoxyhangtaimycin is prepared from the genetically engineered strain ΔhtmP of Streptomyces spectabilis CCTCC M2017417, with a retention time of 20.8 min; or,

[0018] When preparing hangtaimycin A or hangtaimycin B, the alcoholysis derivative of hangtaimycin, each fraction obtained by the medium pressure chromatography column is first detected by HPLC, and the components containing the target product are then dissolved in methanol and alcoholyzed at 42° C. and 0.1% acetic acid for 72 hours;

[0019] S4: After the alcoholysis product is completely detected by LC-ESI-HRMS, it is prepared by high performance liquid chromatography (ODS-A, 250×10 mm, 5 μm, YMC, flow rate of 3 mL / min) with a gradient elution of acetonitrile: water from 45% to 55% by volume fraction, and hangtaimycin A and hangtaimycin B are prepared from Streptomyces spectabilis CCTCC M2017417 and its genetically engineered strain ΔhtmP, respectively, and the retention times of hangtaimycin A and hangtaimycin B are 18.8 min and 21.2 min, respectively. 3. A use of the hangtaimycin derivative as claimed in claim 1 in the preparation of anti-inflammatory, analgesic, anti-tumor, liver injury protection and drug addiction prevention and treatment drugs.

[0020] In a third aspect, the present invention provides an anti-inflammatory drug, characterized in that it contains the hangtaimycin, deoxyhangtaimycin, hangtaimycin A and hangtaimycin B and their derivatives as described above as active ingredients.

[0021] In a fourth aspect, the present invention provides an analgesic drug, characterized in that it is used to treat inflammatory pain and contains hangtaimycin, deoxyhangtaimycin, hangtaimycin A and hangtaimycin B and their derivatives as described above as active ingredients of the drug for treating inflammatory pain.

[0022] In a fifth aspect, the present invention provides an anti-tumor drug, characterized in that it is used to inhibit tumor growth and treat tumors, and contains hangtaimycin, deoxyhangtaimycin, hangtaimycin A and hangtaimycin B and their derivatives as described above as tumor therapeutic active ingredients.

[0023] In a sixth aspect, the present invention provides a liver damage protection drug, characterized in that it contains the above-mentioned deoxyhangtaimycin, hangtaimycin A and hangtaimycin B and their derivatives as active ingredients.

[0024] In a seventh aspect, the present invention provides a drug for preventing and treating drug addiction, characterized in that it is used to prevent and treat the addictiveness of morphine and cocaine drugs, and contains hangtaimycin, deoxyhangtaimycin, hangtaimycin A and hangtaimycin B and their derivatives as mentioned above as active ingredients for preventing and treating drug addiction.

[0025] In the technical scheme of the present invention, the fermentation culture of Streptomyces spectabilis CCTCC M2017417 or the cytochrome P450 gene in-frame knockout engineered mutant strain ΔhtmP is filtered, and the fermentation product is extracted with ethyl acetate, and the ethyl acetate phase is concentrated to prepare a concentrated extract. For the preparation of HTMA, the Streptomyces spectabilis CCTCC M2017417 strain is used for fermentation, and for the preparation of HTMP and HTMB, the cytochrome P450 gene in-frame knockout engineered mutant strain ΔhtmP is used for fermentation.

[0026] The concentrated extract was separated and purified by normal phase silica gel column chromatography, reverse phase medium pressure liquid chromatography, high performance liquid chromatography and alcoholysis to prepare HTMP, HTMA and HTMB respectively.

[0027] The present invention provides the application of HTM and its derivatives in anti-inflammatory, liver protection, analgesia, and treatment of morphine and cocaine addiction. Through activity test experiments, the present invention shows that the HTM derivatives have excellent anti-inflammatory, liver protection, analgesia, and treatment of morphine and cocaine addiction activities.

[0028] Streptomyces spectabilis CCTCC M2017417 involved in the present invention is a known strain, which is disclosed in the following literatures: (1) Functional analysis of cytochrome P450s involved in instreptovaricin biosynthesis and generation of anti-MRSA analogues. Yuanzhen Liu, Xu Chen, Zhengyuan Li, Wei Xu, Weixin Tao, Jie Wu, Jian Yang, Zixin Deng, Yuhui Sun. ACS Chemecal Biology 2017, 12(10): 2589-2597; (2) The mechanism of dehydrating bimodules in trans-acyltransferase polyketide biosynthesis: A showcase study on hepatoprotective HTM. Minghe Luo, Houchao Xu, Yulu Dong, KunShen, Junlei Lu, Zhiyong Yin, Miaomiao Qi, Guo Sun, Lingjie Tang, Jin Xiang, Zixin Deng, Jeroen S. Dickschat, Yuhui Sun. Angewandte Chemmie International Edition 2021, 60(35): 19139-19143. Its cytochrome P450 gene in-frame knockout engineered mutant strain ΔhtmP was constructed by our laboratory on the basis of Streptomyces spectabilis CCTCC M2017417 by in-frame knockout of a P450 gene. The applicant guarantees that the strain Streptomyces spectabilis CCTCCM2017417 and its engineered strain ΔhtmP will be provided to the public within 20 years from the date of application. BRIEF DESCRIPTION OF THE DRAWINGS

[0029] Figure 1 .Chemical structural formulas of HTM and its alcoholysis derivatives (A: derivatives of HTM, B: derivatives of HTM alcoholysis products);

[0030] Figure 2 .htmP gene knockout recombinant plasmid;

[0031] Figure 3 .htmP gene knockout schematic diagram and verification results;

[0032] Figure 4 .Results of high pressure liquid chromatography of fermentation products of htmP gene knockout mutant strain ΔhtmP (* in the figure indicates no HTM detected);

[0033] Figure 5 .High-resolution mass spectrometry results of HTMP;

[0034] Figure 6 .HTMP 1 H NMR test results;

[0035] Figure 7 .HTMP 13 C Nuclear magnetic resonance imaging results;

[0036] Figure 8 .HTMP 1 H- 1 H COZY's NMR test results;

[0037] Fig. 9 .HSQC NMR test results of HTMP;

[0038] Fig.10 .HMBC NMR test results of HTMP;

[0039] Fig.11 .HTMP 1 H- 1 H ROESY NMR test results;

[0040] Fig.12 .HTMA high-resolution mass spectrometry results;

[0041] Fig.13 .HTMA 1 H NMR test results;

[0042] Fig.14 .HTMA 13 C Nuclear magnetic resonance imaging results;

[0043] Fig.15 .HTMA 1 H- 1 H COZY's NMR test results;

[0044] Fig.16 .HSQC NMR test results of HTMA;

[0045] Fig.17 .HMBC NMR test results of HTMA;

[0046] Fig.18 .HTMA 1 H- 1 H ROESY NMR test results;

[0047] Fig.19 .High-resolution mass spectrometry results of HTMB;

[0048] Fig. 20 .HTMB 1 H NMR test results;

[0049] Fig.21 .HTMB 13 C Nuclear magnetic resonance imaging results;

[0050] Fig. 22 .HTMB 1 H- 1 H COZY's NMR test results;

[0051] Fig.23 .HSQC NMR test results of HTMB;

[0052] Fig.24 .HMBC NMR test results of HTMB;

[0053] Fig.25 .HTMB 1 H- 1 H ROESY NMR test results;

[0054] Fig.26 .The results of cell tests on the anti-liver damage activity of HTMA, HTMB and HTMP;

[0055] Fig. 27 .HTMA anti-liver injury test results [Figure: (A) Alanine aminotransferase (ALT); (B) Aspartate aminotransferase (AST); (C) Lactate dehydrogenase (LDH); High (HH), Medium (MH), Low (LH) dose HTMA groups; Obeticholic acid (OBC) and Silymarin (S) groups];

[0056] Fig.28 .HTMA anti-cholestatic test results [Figure: (A) total bile acid (TBA); (B) direct bilirubin (DBIL); (C) total bilirubin (TBIL); (D) gamma-glutamyltransferase (GGT); (E) alkaline phosphatase (ALP); high (HH), medium (MH), and low (LH) dose HTMA groups; obeticholic acid (OBC) and silymarin (S) groups];

[0057] Fig.29.HE staining test results of liver injury modeling [Figure: (A) normal group; (B) liver injury model group];

[0058] Fig.30 .HE staining test results of HTMA against liver injury [Figure: (A) liver injury model group; (B) positive control obeticholic acid group; (C) positive control silymarin group; (D) HTMA low-dose group; (E) HTMA medium-dose group; (F) HTMA high-dose group];

[0059] Fig.31 .HTM, HTMA, HTMB, HTMP anti-inflammatory injury test results [Figure: (A) HTM anti-inflammatory tissue swelling thickness change; (B) HTMP anti-inflammatory tissue swelling thickness change; (C) HTMA anti-inflammatory tissue swelling thickness change; (D) HTMB anti-inflammatory tissue swelling thickness change; (E) positive drug rapamycin anti-inflammatory tissue swelling thickness change; (F) HTM, HTMP, HTMA, HTMB four compound structures of the relationship and blank group and model group were given HTM, HTMP, HTMA, HTMB anti-inflammatory tissue swelling thickness change summary. Physiological saline is the blank group, carrageenan is the model group, **P < 0.05];

[0060] Fig.32 .HTMA and HTMB anti-inflammatory damage HE staining test results;

[0061] Fig.33 .HTMA and HTMB test results on changes in leukocytes against inflammatory damage;

[0062] Fig.34 .HTMB anti-inflammatory and analgesic test results;

[0063] Fig.35 .HTMB prevention drug addiction test results;

[0064] Fig.36 .HTMB treatment drug addiction test results [Figure: Pre-C: baseline value; Post-C: CPP value; Post-T1: test value on the first day after exposure; Post-T7: test value on the seventh day after exposure];

[0065] Fig.37 .HTM, HTMA, HTMB, HTMP antioxidant activity test results;

[0066] Fig.38 .HTM, HTMA, HTMB, and HTMP anti-tumor activity test results. DETAILED DESCRIPTION

[0067] The technical solution of the present invention is further described in detail below in conjunction with the embodiments and drawings.

[0068] Example 1 Construction of a cytochrome P450 gene knockout mutant strain ΔhtmP of Streptomyces spectabilis CCTCC M2017417

[0069] (1) Based on the nucleotide sequence of the biosynthetic gene cluster of HTM, a pair of primers were designed upstream and downstream of the cytochrome P450 encoding gene htmP in the biosynthetic gene cluster of HTM (Table 1), and the left and right homologous exchange arms for homologous recombination were obtained by PCR amplification, with lengths of 1936 bp and 2236 bp, respectively. The PCR reaction system and conditions were:

[0070] dH 2 O 48 μL

[0071] 2×Phanta Max Buffer 25μL

[0072] dNTP Mix (10mM each) 1μL

[0073] Upstream primer (10 μM) 2 μL

[0074] Downstream primer (10 μM) 2 μL

[0075] Phanta Max Super-Fidelity DNA Polymerase 1μL

[0076] Template DNA 2 μL

[0077] 95℃3:00min

[0078] 95℃0:30min

[0079] 58℃0:30min

[0080] 72℃1:30min(30cycles)

[0081] 72℃5min

[0082] (2) The E. coli and Streptomyces shuttle vector pYH7 was double-digested with restriction endonucleases NdeI and HindIII, and a DNA fragment of about 9 kb containing the conjugative transfer initiation replication site and the ampicillin resistance gene was recovered as a vector. The DNA fragment was spliced ​​with the two left and right homologous arms mentioned above by the Gibson method to obtain the htmP gene in-frame knockout recombinant plasmid pWHUP450 ( Figure 2 ).

[0083] (3) The recombinant plasmid pWHUP450 was transformed into E. coli DH10B competent cells and cultured overnight at 37°C. Positive single clones were picked from the plate, the plasmids were extracted, and the clones were verified by restriction digestion and sequencing.

[0084] (4) The verified recombinant plasmid pWHUP450 was transformed into the E. coli ET12567 / pUZ8002 strain. The E. coli ET12567 / pUZ8002 monoclonal transformant containing the recombinant plasmid was inoculated into 5 mL of 2×TY liquid medium (1.6% tryptone, 1% yeast extract powder, 0.5% NaCl) containing antibiotics kanamycin (Kanamycin, 50 μg / mL) and apramycin (Apramycin, 25 μg / mL), and cultured at 37°C overnight. The bacterial liquid was inoculated at 10% inoculum into 5 mL of 2×TY culture medium containing antibiotics kanamycin (25 μg / mL) and apramycin (12.5 μg / mL), and cultured at 37°C for 3 h.

[0085] (5) Mycelia of Streptomyces spectabilis CCTCC M2017417 cultured in TSBY liquid medium (sucrose 10.5%, yeast extract powder 0.5%, soybean extract 0.5%) for 48 h were washed twice with 2×TY liquid medium, and 100 μL of the mixture was mixed with 100 μL of Escherichia coli ET12567 / pUZ8002 containing the recombinant plasmid washed twice with 2×TY liquid medium, and then spread on ABB13 solid medium (soluble starch 0.5%, soy peptone 0.5%, calcium carbonate 0.3%, 3-(N-morpholino)propanesulfonic acid 0.21%, thiamine hydrochloride 0.001%, ferrous sulfate heptahydrate 0.0012%, agar 2%). After culturing at 28°C for 12 h, add 1 mL of sterile water containing the antibiotics nalidixic acid (25 μg / mL) and apramycin (35 μg / mL) to cover the culture medium. After the surface of the culture medium is dry, culture it at 28°C. After 5-7 days, obvious growth of conjugative transferases can be seen.

[0086] (6) Spread the conjugative transfer product on ABB13 solid culture medium plates and culture them at 28°C. After 5-7 days, obvious single colony growth can be seen.

[0087] (7) Single colonies were spread on ABB13 solid culture medium plates containing antibiotic apramycin (35 μg / mL) and without antibiotics. After 5 to 7 days, strains that grew on plates without antibiotics but did not grow on plates containing antibiotic apramycin were selected as candidate target strains. Their genomic DNA was extracted, and a pair of primers (Table 2) were designed in the upstream and downstream regions of the knockout DNA for PCR verification ( Figure 3). The verified correct strain is the cytochrome P450 gene in-frame knockout engineered mutant strain ΔhtmP.

[0088] Table 1. Primers and nucleotide sequences for constructing htmP gene knockout recombinant plasmid

[0089]

[0090] Table 2. Primers and nucleotide sequences for verification of htmP gene in-frame knockout mutants

[0091]

[0092] Example 2 Highly efficient preparation method of HTMP

[0093] (1) Fermentation

[0094] 1) Place a 1 cm-sized plate on the ABB13 solid culture medium. 2 The bacterial mass of the gene in-frame knockout mutant strain ΔhtmP of Streptomyces spectabilisCCTCC M2017417 was inoculated into 200 mL of TSBY liquid culture medium and cultured at 28°C and 220 rpm for 20 h to prepare seed solution.

[0095] 2) The above seed solution was inoculated into 10 L SFMR fermentation medium at an inoculum rate of 2%, and cultured at 28° C. and 220 rpm for 4 days to prepare a fermentation culture.

[0096] (2) Extraction

[0097] 1) Pass the fermentation culture through a sieve (100-200 mesh) to separate the fermentation liquid from the mycelium and the macroporous resin.

[0098] 2) The mycelium and macroporous resin were extracted three times with 8 L of ethyl acetate. The ethyl acetate phases were combined and concentrated by vacuum distillation to obtain about 7.8 g of extract.

[0099] (3) Separation

[0100] 1) The concentrated extract was subjected to normal phase silica gel column chromatography, with chloroform / acetonitrile as the eluent, and gradient elution was performed in a volume ratio from 100:0 to 50:50, and the fractions eluted with a volume ratio of chloroform:acetonitrile from 70:30 to 50:50 were collected.

[0101] 2) The fraction containing the target compound was further subjected to ODS reverse phase medium pressure liquid chromatography (S-50 μm, 12 nm, 26×300 mm, flow rate 13 mL / min) with acetonitrile / water as the eluent and gradient elution from 0:100 to 100:0 by volume ratio.

[0102] 3) The target compound-containing fractions were finally purified by HPLC (ODS-A, 250×10 mm, 5 μm, YMC, flow rate 3 mL / min) using a gradient elution of acetonitrile:water from 45% to 55% by volume, and the compound with a retention time of 20.8 min was collected.

[0103] (4) Identification

[0104] High-resolution mass spectrometry of the HTM intermediate produced by the ΔhtmP mutant showed that this intermediate (C 50 H 61 N 7 O 10 ) is only better than HTM(C 50 H 61 N 7 O 11 ) has one less oxygen atom in molecular weight. By comparing and analyzing the NMR spectrum data, it is found that the methoxy NMR signal δ H 5.36, dd (13.2, 7.2) and δ C 73.4 in this intermediate is replaced by a methylene NMR signal δ H 3.39, dd (13.2, 7.2) and δ C 42.5 signal, this intermediate is C 42 The position of the methoxy group should be a methylene group, which is consistent with the data reported in the literature (Li et al. 2022), and it was identified as HTMP.

[0105] Table 3. HTMP 13 C and 1 H NMR data attribution

[0106]

[0107]

[0108] Example 3 Highly efficient preparation method of HTMA and HTMB

[0109] (1) Fermentation

[0110] 1) Place a 1 cm-sized plate on the ABB13 solid culture medium. 2 The bacterial blocks of Streptomyces spectabilisCCTCC M2017417 (used for fermentation to prepare HTMA) or its gene in-frame knockout mutant strain ΔhtmP (used for fermentation to prepare HTMB) were inoculated into 200 mL of TSBY liquid culture medium and cultured at 28°C and 220 rpm for 36 h to prepare seed solution.

[0111] 2) The seed liquid was inoculated into 10 L SFMR liquid fermentation medium at an inoculum amount of 2%, and cultured at 28° C. and 220 rpm for 108 h to prepare a fermentation culture.

[0112] (2) Extraction

[0113] 1) Pass the fermentation culture through a sieve (100-200 mesh) to separate the fermentation liquid from the mycelium and the macroporous resin.

[0114] 2) The mycelium and macroporous resin were extracted three times with 10 L of ethyl acetate. The ethyl acetate phases were combined and concentrated by vacuum distillation to obtain about 8.5 g of extract.

[0115] (3) Separation

[0116] 1) The concentrated extract was subjected to normal phase silica gel column chromatography, with chloroform / methanol as the eluent, and gradient elution was performed in a volume ratio from 100:0 to 80:20, and the fractions eluted with a volume ratio of chloroform:methanol from 96:4 to 94:6 were collected.

[0117] 2) The fractions containing the target product were further subjected to ODS reverse phase medium pressure liquid chromatography (S-50μm, 12nm, 26×300mm, flow rate 13mL / min), using acetonitrile / water as the eluent, and gradient elution was performed from 0:100 to 100:0 by volume ratio. The fractions containing the target product detected by HPLC were then dissolved in methanol and alcoholyzed at 42°C and 0.1% acetic acid for 72h.

[0118] 3) The above fractions were finally purified by high performance liquid chromatography (ODS-A, 250×20 mm, 5 μm, YMC, flow rate of 3 mL / min) with a gradient elution of acetonitrile:water from 45% to 55% by volume, to prepare HTMA and HTMB from Streptomyces spectabilisCCTCC M2017417 or the gene in-frame knockout mutant ΔhtmP, with retention times of 18.8 min (HTMA) and 21.2 min (HTMB) on the liquid phase, respectively.

[0119] (4) Identification

[0120] The HTMA and HTMB prepared above were detected by high-resolution mass spectrometry ( Fig.12 (HTMA), Fig.19 (HTMB)) and NMR spectroscopy identification ( Figures 13 to 18 (HTMA), Figures 20 to 25 (HTMB)), and its NMR data are shown in Table 4. HTMA was identified by high-resolution mass spectrometry and its molecular formula was determined to be C 51 H 66 N7 O 12 ,m / z 968.4756([M+H] + , theoretical value C 51 H 66 N 7 O 12 ,968.4764). 1 The H spectrum showed that it contained 18 olefin proton signals, 5 amino / amide proton signals, and 8 methyl proton signals (including δ H 3.23,3.57 two oxygen-containing methyl groups and δ H 2.88), 5 methylene and 6 methine proton signals. 13 C-NMR and HSQC spectra further assigned 1 The remaining unrevealed signals in the H spectrum showed that HTMA contained 15 quaternary carbons, including 8 amide or ester carbonyl groups and 7 sp 2 Unsaturated quaternary carbon. 1 H- 1 The correlation signals of NH-1 / H-2, H-4 / H-5 / H-6 / H-7 in the H COSY spectrum and the related signals NH-1 / C-3, C-9; H-2 / C-3, C-8 and C-9; H-4 / C-3, C-6, C-8, C-9; H-5 / C-4, C-6, C-7, C-9; H-7 / C-5, C-6, C-8, C-9 in the HMBC spectrum indicate that there is a C-3 substituted indole structural unit in the compound. The chemical shifts of the two amide carbonyl groups are at δ C The chemical shifts at 167.8 (C-13), 171.2 (C-16) and a single methoxy signal (δ H 3.57, δ C 51.8), and H 3 -18 / C-17, C-14; H-17 / C-13, C-14, C-18; H-11 / C-3, C-10, C-16; N-CH 3 HMBC correlation of C-11 and C-13 indicated the presence of a ring-opened dipeptide building block. 1 H- 1 The related signals of H COSY and HMBC can be further classified into C-20 / C-21 (21-OCH 3) / C-22; C-25 / C-26; C-29 / C-30 / C-31 / C-32 / C-33 / C-34 / C-35; C-37 / C-38 / C-42; C-45 / C-46 / C-47 / C-48 / C-49, C-52 / C-53 / C-54 / C-55 / C-56 six spin-coupled fragments. The HMBC related signals of H-20 / C-19, C-24; NH-23 / C-19, C-20, C-24; NH-27 / C-24, C-25, C-28, C-29; H-29 / C-28; H-35 / C-36, C-37, C-40, C-41; H-38 / C-40, C-36; H-42 / C-44; H-46 / C-44, C-47; H-47 / C-44, C-48, C-49; H-48 / C-47, C-51; NH-50 / C-48, C-51, C-52 connect these five spin-coupled fragments into a long fragment of C19-C56. This long fragment is further connected to the dipeptide part through the peptide bond formed by C-19, which is consistent with its chemical shift of δ C 168.2 (C-19). The NMR data of the compound isolated from the mutant strain ΔhtmP are very similar to HTMA, with the only difference being that there is one less O atom in the high-resolution mass spectrum and the methoxy signal at the C42 position is replaced by a methylene signal. In summary, the two new compounds were identified and named HTMA and HTMB, respectively, with the structural formulas shown below. Figure 1 As shown in B.

[0121] Table 4. HTMA and HTMB 13 C and 1 H NMR data attribution

[0122]

[0123]

[0124] Example 4 Cellular test of HTMA, HTMB and HTMP for repairing liver damage

[0125] Human hepatoma cell line HepG2 was cultured in 24-well plates at 37°C and 5% CO 2 Cultivate in an incubator until 80% 4 A liver injury cell model was established. After drug administration, the cells were ultrasonically disrupted and homogenates were prepared to detect the effects of HTMA, HTMB, and HTMP on the activities of alanine aminotransferase ALT and aspartate aminotransferase AST, and the results were compared with those of silymarin (positive control) treatment ( Fig.26 ).

[0126] The results of the liver injury cell model showed that CCl 4 Compared with the blank control group, the ALT and AST indexes in the CCl group were significantly increased, proving that the model was successful. 4 Compared with the control group, the ALT and AST indexes of the three compounds HTMA, HTMB and HTMP were significantly reduced, indicating that these three compounds have the activity of repairing liver damage.

[0127] Example 5 Animal test of HTMA's activity in repairing liver damage

[0128] Male Wistar rats weighing about 220g were randomly divided into 7 groups, with 12 rats in each group. After grouping, the rats were fed with a standard diet under standard conditions and continuously gavaged. The doses of obelcholinic acid and silymarin in the two positive control groups were 10mg / kg and 5mg / kg, respectively. HTMA administration was divided into three dose groups: low, medium and high dose groups at doses of 2.5, 5 and 10mg / kg. The control group and the model group were gavaged with 0.5% sodium carboxymethyl cellulose (cosolvent) daily. After 7 days of administration, the rats were fasted for 12h. After weighing on the 8th day, rats in all groups except the control group were intraperitoneally injected with α-naphthyl isothiocyanate (50mg / kg, the solvent was olive oil) for modeling. The rats in the control group were intraperitoneally injected with the solvent olive oil. After two days of continued administration, the rats were fasted for 12h, and blood samples were taken to reflect liver cell damage ( Fig. 27 ) and cholestasis ( Fig.28 ) level of biochemical indicators, and the liver was taken for immunohistochemical testing ( Fig.29 and Fig.30 ).

[0129] The results of biochemical index detection showed that all indicators in the liver injury model group were significantly higher than those in the control group, proving that the model was successful. Compared with the liver injury model group, high-dose HTMA (HH group) can significantly reduce the levels of alanine aminotransferase ALT, aspartate aminotransferase AST, lactate dehydrogenase LDH, total bile acid TBA, total bilirubin TBIL, γ-glutamyl transferase GGT and alkaline phosphatase ALP, confirming that HTMA has anti-liver injury and cholestasis effects. Medium and low doses of HTMA (MH, LH groups), obeticholic acid (O group) and silymarin (S group) all significantly reduced the level of lactate dehydrogenase LDH, and their effects on other biochemical indicators were weaker than high-dose HTMA, indicating that the high-dose group HTMA has a stronger effect on anti-cholestasis and liver injury.

[0130] The results of immunohistochemistry showed that compared with the control group, the liver injury model group had mild overall tissue enlargement, mild dilation of the hepatic sinusoids in some areas, fatty degeneration of a small number of hepatocytes, fat droplets located on one side of the cell nucleus, and fibrosis and hyperplasia around the central vein accompanied by more inflammatory cell infiltration, confirming that the model was successful ( Fig.29 ). Compared with the liver injury model group, the liver portal area arrangement structure in all HTMA-administered groups was normal, the hepatocytes were regularly arranged into liver plates, the liver plates were radially arranged with the central vein as the center, the size of the hepatic sinusoids was normal, and inflammatory cells were occasionally found in the perivascular infiltration. No edema or other pathological changes were observed, indicating that all HTMA-administered groups had an improvement effect on the pathological conditions of liver tissue injury ( Fig.30 ).

[0131] Example 6 Anti-inflammatory damage test of HTM and its derivatives

[0132] 18-22g Kunming male mice were selected and fed for 1 day, and then randomly divided into 10 groups, with 5-6 mice in each group, for the inflammatory swelling experiment of mouse foot plantar induced by 1% carrageenan. The groups were: saline + vehicle group, saline + HTM group, saline + HTMP group, saline + HTMA group, saline + HTMB group, saline + rapamycin (250nM) group, carrageenan + vehicle group, carrageenan + HTM group, carrageenan + HTMP group, carrageenan + HTMA group, carrageenan + HTMB group, carrageenan + rapamycin (250nM) group, among which HTM, HTMP, HTMA and HTMB were set at 1mg / mL, 3mg / mL and 10mg / mL, and all solutions contained 5% DMSO. The model was established and the experiment was carried out according to the reference (Zhang et al. 2018). The brief experimental process is as follows:

[0133] (1) Before the experiment, the thickness of the right hind foot of the mouse was measured with a vernier caliper and the measurement site was marked.

[0134] (2) Then, mice were subcutaneously injected with 10 μL of compound solutions of different concentrations in the right hind foot pad. The experimental group received the compound, and the control group received an equal amount of saline.

[0135] (3) After administration, the carrageenan group was subcutaneously injected with 30 μL of 1% carrageenan solution in the right hind paw pad, and the other groups were injected with an equal volume of normal saline. The thickness of the right hind paw of each mouse was measured at the same location every 1 h within 4 h to observe the effect of the compound on the change of paw thickness.

[0136] The results show that Figure 31-33), the baseline difference of the thickness of the right hind foot of mice in the carrageenan + HTMP (10 mg / mL) group, carrageenan + HTMA (10 mg / mL) group and carrageenan + HTMB (10 mg / mL) group after 4 hours was statistically different from that in the carrageenan + vehicle group (P < 0.05), and the carrageenan + HTMB (10 mg / mL) group was statistically different from the carrageenan + HTMP (10 mg / mL) group and the carrageenan + HTMA (10 mg / ml) group (P < 0.05). In addition, the HE staining results showed that the number of white blood cells per unit area in the carrageenan + HTMB (10 mg / mL) group was statistically different from that in the carrageenan + vehicle group relative to the control group (P < 0.05). The above results show that HTMP, HTMA and HTMB can all improve the inflammation caused by carrageenan, among which HTMB has the best effect.

[0137] Example 7 Analgesic Activity Test of HTMB

[0138] Acetic acid writhing test: 18-22g Balb / c male mice were selected and randomly divided into four groups, with 9-10 mice in each group. The groups were: vehicle group (DMSO: saline = 1:4, 1mL / kg), HTMB (1mg / kg) group, HTMB (3mg / kg) group, and HTMB (10mg / kg) group. Each group was intraperitoneally injected with freshly prepared 0.6% acetic acid 10mL / kg (Rediet Tesfaye, et al. 2020) 30 minutes after tail vein administration, and the number of mouse writhing times within 20 minutes was observed and recorded. The experimental results showed ( Fig.34 ), the number of body twisting in the HTMB (3 mg / kg) and HTMB (10 mg / kg) groups was lower than that in the vehicle group, and the difference was statistically significant (P < 0.05). This indicates that HTMB has an analgesic effect on acute inflammatory visceral pain caused by acetic acid.

[0139] Example 8 HTMB Prevention and Treatment of Drug Addiction Activity Test

[0140] Conditioned place preference (CPP) formation experiment: Morphine, a representative of opioid drugs, and cocaine, a representative of stimulant drugs, were used to build the model. On the first day, the passage between the three boxes was opened, and the rats were allowed to move freely in the three boxes for 15 minutes, and the basal value was measured. Then the SD male rats were divided into saline + morphine group, HTMB (3 mg / kg) + morphine group, saline + cocaine group, and HTMB (3 mg / kg, ip) + cocaine group for conditioned place preference training. From the second to the ninth day, the rats were trained in conditioned place preference on the drug-accompanying side and the non-drug-accompanying side. On the tenth day, the passage between the three boxes was opened, and the rats were allowed to move freely in the three boxes for 15 minutes, and the conditioned place preference test was performed.

[0141] The results showed that there was a significant statistical difference in the CPP scores before and after treatment between the saline + morphine group and the HTMB + morphine group (P<0.05), indicating that HTMB can inhibit the formation of morphine CPP.

[0142] Conditioned place preference (CPP) memory reconsolidation experiment: Morphine, a representative of opioid drugs, and cocaine, a representative of stimulant drugs, were used to build the model. On the first day, the passage between the three boxes was opened, and the rats were allowed to move freely in the three boxes for 15 minutes, and the basal value was measured. Then the SD male rats were divided into saline group, morphine group and cocaine group for conditioned place preference training. From the second to the ninth day, the rats were trained in conditioned place preference on the drug-accompanying side and the non-drug-accompanying side. On the tenth day, the passage between the three boxes was opened, and the rats were allowed to move freely in the three boxes for 15 minutes, and the conditioned place preference test was performed. On the eleventh day, the CPP formation rats were screened and divided into four groups. The first group was the morphine + saline group, the second group was the morphine + HTMB (3 mg / kg) group, the third group was the cocaine + saline group, and the fourth group was the cocaine + HTMB (3 mg / kg) group. After the rats were exposed to the drug box-related environmental cues for 10 minutes, the first and third groups were injected with saline (1ml / kg, ip), and the second and fourth groups were injected with HTMB (3mg / kg, ip). 24 hours later, that is, on the first day after the reward memory was activated, and on the seventh day after the reward memory was activated, the CPP scores were measured. The results showed that the CPP scores of the first and second groups were statistically significantly different (P<0.05), and the CPP scores of the third and fourth groups were statistically significantly different (P<0.05). This shows that HTB can block the reconsolidation of morphine and cocaine reward memory.

[0143] The above experimental results ( Figures 35-36 ) indicates that HTMB has the effect of preventing and treating drug addiction.

[0144] Example 9 Determination of Antioxidant Activity of HTM and Its Derivatives

[0145] Take 10 μL of the test solution and 90 μL of 3×10 -5 1 mol / L 2,2-diphenyl-1-picrylhydrazyl (DPPH) solution was added to the same well of the 96-well plate and gently shaken. A mixture of 10 μL sample solvent and 90 μL ethanol was used as a blank group, and 10 μL sample solvent and 90 μL 3×10 -5 A mixture of 1 mol / LDPPH solution was used as a control, and its absorbance As was measured at 517 nm using an enzyme reader after 12 h.

[0146] The clearance rate was calculated according to the following formula:

[0147] DPPH free radical scavenging rate / % = (A 0-As) / A 0 × 100%, where A 0 is the absorbance value of 10 μL solvent + 90 μL DPPH solution; As is the absorbance value of 10 μL sample solution + 90 μL DPPH solution.

[0148] result( Fig.37 ) showed that HTM, HTMB, and HTMP all exhibited certain antioxidant effects, while HTMA had no obvious antioxidant effect.

[0149] Example 10 Determination of anticancer activity of HTM and its derivatives:

[0150] Cultivate cancer cells, collect logarithmic phase cancer cells and inoculate them into 96-well plates, add 100 μL to each well, and adjust the cell density to 8000 / well. 5% CO 2 , cultured at 37°C until the cell monolayer covered the bottom of the well, switched to RPMI 1640 medium without phenol red, added samples of concentration gradient, and 5% CO 2 , culture at 37℃ for 24h. Add 10μL MTT solution (5mg / mL) to each well and continue to culture for 4h. Terminate the culture, discard the culture solution, rinse twice with PBS, add 100μL DMSO to each well, and shake gently to fully dissolve the crystals.

[0151] The absorbance of each well was measured at 570 nm using an ELISA reader. At the same time, blank zero adjustment wells (culture medium, MTT, DMSO) and control wells (cells, sample solvents of the same concentration, culture medium, MTT, DMSO) were set up, and 5 replicate wells were set up for each group.

[0152] Cell survival rate / % = (absorbance of experimental group - absorbance of blank group) / (absorbance of control group - absorbance of blank group) × 100%

[0153] result( Fig.38 ) showed that HTP had strong anticancer activity, and 50μg / mL could significantly inhibit the survival rate of bladder cancer, kidney cancer, liver cancer and breast cancer (P<0.01). 50μg / mL HTM and HTMB could significantly inhibit the survival rate of bladder cancer, kidney cancer and breast cancer (bladder cancer, P<0.01; kidney cancer, P<0.01; breast cancer, P<0.05). 50μg / mL HTMA could significantly inhibit the survival rate of bladder cancer and breast cancer (P<0.01).

Claims

1. A Hangtaimycin derivative, characterized in that: The derivatives are alcoholysis derivatives hangtaimycin A and hangtaimycin B, and their chemical structures are shown below: 。 2. A method for preparing a hangtaimycin derivative as claimed in claim 1, characterized in that The following steps are included: S1: Streptomyces spectabilis CCTCCM2017417 or its cytochrome P450 gene in-frame knockout mutant strain ΔhtmP is inoculated into SFMR medium for culture, wherein the SFMR medium comprises the following components: 2% soybean powder, 2% mannitol, and 5% AB-8 macroporous adsorption resin, to prepare a fermentation culture; The preparation of hangtaimycin B uses the cytochrome P450 gene in-frame knockout mutant strain ΔhtmP of Streptomyces spectabilis CCTCCM2017417; the preparation of hangtaimycin A uses Streptomyces spectabilis CCTCCM2017417; S2: separating the solid and liquid of the fermentation culture in step S1, extracting with ethyl acetate, and combining the extracts; subjecting the extracts to normal phase silica gel column chromatography, using a chloroform:methanol mixed solvent with a volume ratio ranging from 100:0 to 90:10 for gradient elution, and collecting fractions with a chloroform:methanol volume ratio of 96:4 to 94:6; S3: The fraction containing the target product hangtaimycin A or hangtaimycin B in S2 was subjected to ODS reverse phase medium pressure liquid chromatography S-50μm, 12nm, 26×300mm, flow rate 13mL / min, acetonitrile / water as eluent, and gradient elution was performed in a volume ratio from 0:100 to 100:0: The fractions obtained by the above reverse phase medium pressure liquid chromatography were first detected by HPLC, and the components containing the target product were dissolved in methanol and alcoholyzed at 42°C and 0.1% acetic acid for 72h; S4: After the alcoholysis product was completely decomposed by LC-ESI-HRMS, hangtaimycin A and hangtaimycin B were prepared by high performance liquid chromatography ODS-A, 250×10 mm, 5 μm, YMC, with a flow rate of 3 mL / min and gradient elution of acetonitrile: water in a volume fraction ratio of 45% to 55%. The retention times of hangtaimycin A and hangtaimycin B were 18.8 min and 21.2 min, respectively.

3. A drug for treating inflammatory swelling, characterized in that: Containing the hangtaimycin A and / or hangtaimycin B according to claim 1.

4. An analgesic drug, characterized in that: For use in treating inflammatory visceral pain, comprising the hangtaimycin B of claim 1.

5. An anti-tumor drug, characterized in that: For inhibiting tumor growth, comprising the hangtaimycin A and / or hangtaimycin B according to claim 1.

6. A liver damage protection drug, characterized in that: Containing the hangtaimycin A and / or hangtaimycin B according to claim 1.

7. A drug for preventing and treating drug addiction, characterized in that: For preventing and treating opioid addiction, comprising hangtaimycin A and / or hangtaimycin B as claimed in claim 1.

8. Use of a hangtaimycin derivative in the preparation of a drug for treating inflammatory swelling or liver damage, characterized in that: The hangtaimycin derivative is one or more of deoxyhangtaimycin, hangtaimycin A, and hangtaimycin B. The structures of hangtaimycin A and hangtaimycin B are as shown in claim 1. The structure of deoxyhangtaimycin is as shown in the following formula: .

9. Use of hangtaimycin derivatives in the preparation of drugs for preventing and treating opioid addiction or for treating inflammatory visceral pain, characterized in that: The hangtaimycin derivative is hangtaimycin B, and the structure of hangtaimycin B is as shown in claim 1.

10. Use of a hangtaimycin derivative in the preparation of a drug for treating cancer, characterized in that: The Hangtaimycin derivative is deoxyhangtaimycin, the cancer is bladder cancer, kidney cancer, liver cancer, breast cancer, and the structure of the deoxyhangtaimycin is shown in the following formula: ; Alternatively, the hangtaimycin derivative is hangtaimycin A, the cancer is bladder cancer or breast cancer, and the structure of hangtaimycin A is as shown in claim 1; Alternatively, the hangtaimycin derivative is hangtaimycin B, the cancer is kidney cancer, bladder cancer, breast cancer, and the structure of hangtaimycin B is as shown in claim 1.